Physician profile
Muhammad Noor
NPI 1164628376
$7,285.17
in general payments reported to CMS, 2019-2025
29 companies · $964 in 2025
The $964 reported for 2025 was more than what 89% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $972 · 2020: $448 · 2021: $740 · 2022: $1,971 · 2023: $1,072 · 2024: $1,117 · 2025: $964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,153.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $826.22 | 2021-2025 | Kimyrsa, Orbactiv, Rezzayo |
| Abbvie INC. | $752.93 | 2021-2025 | |
| Pfizer INC. | $734.54 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $677.32 | 2019-2025 | Camzyos, Eliquis |
| Shionogi INC | $646.52 | 2021-2024 | Fetroja |
| Astrazeneca Pharmaceuticals LP | $578.24 | 2019-2025 | Airsupra, Lokelma, Breztri |
| Otsuka America Pharmaceutical, INC. | $361.91 | 2023-2025 | Rexulti, Nuedexta |
| Merck Sharp & Dohme LLC | $361.72 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Janssen Pharmaceuticals, INC | $353.34 | 2019-2024 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $293.06 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.03 | 2019-2024 | Jardiance |
| Acadia Pharmaceuticals INC | $215.44 | 2022-2024 | Nuplazid |
| Novartis Pharmaceuticals Corporation | $169.23 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2023 | |
| Amgen INC. | $124.96 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $120.00 | 2022 | |
| Mylan Specialty L.P. | $95.28 | 2021-2022 | |
| La Jolla Pharmaceutical Company | $93.76 | 2023-2025 | Xerava, Xacduro |
| Lilly USA, LLC | $90.00 | 2019 | |
| Gilead Sciences, INC. | $85.53 | 2023-2025 | Yeztugo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $81.21 | 2023-2024 | Lifevest |
| Avanir Pharmaceuticals, INC. | $60.64 | 2019 | |
| Bioxcel Therapeutics, INC. | $28.21 | 2023 | Igalmi |
| Abbott Laboratories | $24.67 | 2023 | Supera |
| Allergan, INC. | $23.77 | 2019-2020 | |
| Reprise Biomedical, INC. | $19.92 | 2023 | Miroderm, Miro3d |
| Paratek Pharmaceuticals, INC. | $19.92 | 2021 | |
| Medtronic Vascular, INC. | $16.50 | 2019 | |
| Smith+Nephew, INC. | $16.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Noor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.